生产企业：Johnson & Johnson
JNJ-79635322 (ramantamig) is a first-in-class trispecific T-cell-engaging antibody developed by Johnson & Johnson that simultaneously binds CD3ε on T cells and the BCMA and GPRC5D antigens on myeloma cells. It is in clinical development (Phase 1, NCT05652335 and NCT06768489) for relapsed/refractory multiple myeloma, and is regarded as being in late-stage development.
JNJ-79635322 (ramantamig) is a first-in-class trispecific T-cell-engaging antibody developed by Johnson & Johnson that simultaneously binds CD3ε on T cells and the BCMA and GPRC5D antigens on myeloma cells. It is in clinical development (Phase 1, NCT05652335 and NCT06768489) for relapsed/refractory multiple myeloma, and is regarded as being in late-stage development.
T-cell-engaging trispecific antibody (TsAb) that binds the CD3ε subunit of the T-cell receptor complex on T cells together with the tumor antigens BCMA and GPRC5D on myeloma cells, redirecting T cells to induce T-cell-mediated cytotoxicity.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
